Our aim was to assess the clinical effects of myocardial injury after transcatheter aortic-valve implantation (TAVI). Between October 2013 and July 2016, 157 patients underwent TAVI with Sapien XT, Sapien 3, or CoreValve prostheses at our institute. Of these, 130 patients for whom the transapical approach was not used were included in this study. Myocardial injury was defined as a peak troponin I level of ! 1.5 ng/mL within 48 hours after TAVI. We evaluated the predictors of myocardial injury and compared the clinical outcomes of 82 patients classified as the myocardial injury group and 44 patients classified as the non-myocardial injury group. The patients were aged 85 6 years. Myocardial injury occurred in 82 patients (65.1%). Age (per 1 increase) (odds ratio [OR]: 1.11, 95% confidence interval [CI]: 1.01-1.22, P = 0.041), female sex (OR: 3.88, 95% CI: 1.23-12.22, P = 0.021), valve type (Sapien XT; OR: 4.22, 95% CI: 1.15-15.47, P = 0.03, Core valve; OR: 18.12, 95% CI: 2.86-114.59, P = 0.002), balloon aortic valvuloplasty as a bridge therapy (OR: 0.10, 95% CI: 0.02-0.42, P = 0.002), and left ventricular end-diastolic volume (LVEDV) (per 1 increase) (OR: 0.97, 95% CI: 0.95-0.99, P = 0.003) were associated with myocardial injury in a multivariate model. The myocardial injury group did not have a higher rate of midterm (365-day) mortality (log-rank test P = 0.57) than the non-myocardial injury group on Kaplan-Meier analysis. Myocardial injury after TAVI was not associated with midterm mortality.
T ranscatheter aortic-valve implantation (TAVI) an increasingly common procedure for patients in Japan. 1, 2) TAVI is important in the management of severe aortic stenosis.
3) However, myocardial injury is a common phenomenon in TAVI. [4] [5] [6] [7] Myocardial injury after TAVI is caused by many factors such as acute aortic regurgitation, elevation of left ventricular ejection fraction, temporary mitral valve regression, hypotension of coronary artery flow during rapid ventricular pacing, coronary ostia occlusion following valve deployment, direct myocardial injury by wire, suicide left ventricle, and particle embolization into the coronary arteries. 5, [8] [9] [10] [11] [12] [13] [14] [15] (Figure 1 ) Elevated troponin level is an index of myocardial injury. Previous studies show that myocardial injury is significantly associated with a high rate of mortality. 4, 6, 16, 17) However, a recent study found that myocardial injury was not related to 30-day and 1-year mortality. 8, 18) The clinical importance of myocardial injury following TAVI remains unclear. Our aim in this study was to assess the incidence, predictors, and midterm clinical outcomes of myocardial injury after TAVI.
Methods
This was a retrospective, observational cohort study of prospectively collected data from successive patients treated with TAVI at Teikyo University Hospital. Between October 2013 and July 2016, 157 patients underwent TAVI with Sapien XT (XT: Edwards Lifesciences, Irvine, California, USA), Sapien 3 (S3: Edwards Lifesciences, Irvine, California, USA), or CoreValve (CoreValve: Medtronic, Irvine, California, USA) prostheses at our institute. Of these, 130 patients for whom the transapical approach was not used were included in this study. Four patients without troponin I sampling because of periprocedural death were also excluded from the analysis (Figure 2 ). All patients enrolled in the study underwent screening, physical examination, baseline laboratory examination, transthoracic echocardiography, multi-slice computed tomography, and coronary angiography. The indication for TAVI was decided based on the clinical consensus of a multidisciplinary team. The inclusion criteria were (1) the presence of symptoms, (2) degenerative aortic stenosis with a New York Heart Association class II or greater and (3) an aortic-valve area < 1.0 cm 2 (or an effective orifice Nara, ET AL area index < 0.6 cm 2 /m 2 ). The exclusion criterion was the use of dialysis. All patients provided written informed consent before participating in the study. This study was approved by an institutional review board (No. 14-045, 14-045-2). The current study protocol was developed in accordance with the Declaration of Helsinki. Blood Sampling and Analysis: Venous blood samples were drawn before the procedure and at 1 hour, 1 day, and 2 days after the procedure. We adopted the highest values obtained. Myocardial injury was defined as a peak troponin I level !1.5 ng/mL after TAVI, based on previous studies 8, 19) and the Valve Academic Research Consortium (VARC)-2 criteria. 20) Prior to analysis, the blood samples were centrifuged at 3000 rpm for 10 minutes and immediately measured. The serum levels of troponin I were determined using a luminescent oxygen channeling immunoassay (Siemens Dimension Vista 1500: Siemens Healthcare Diagnostics, Tarrytown, NY, USA). The upper reference limit was set at 0.10 ng/mL in accordance with a previous study.
21)
Endpoints and follow-up: The main endpoint of this study was the prediction of myocardial injury. The secondary endpoint was the relationship between myocardial injury and clinical outcomes. The clinical outcomes were all-cause mortality, acute heart failure, postoperative onset of atrial fibrillation, and postoperative pacemaker implantation. Statistical analysis: All statistical analyses were performed using SPSS version 24.0 (IBM, Armonk, NY, USA). We used the Shapiro-Wilk test to assess continuous variables for normal distribution. The data were presented as interquartile range (IQR: 25%-75%) or mean ± standard deviation. The t-test was used to compare the mean values of normally distributed data and the Mann-Whitney U-test was used to compare the mean values of nonnormally distributed data. Dichotomous variables were presented as numbers and percentages. Chi-square tests were used to compare categorical variables (e.g., sex and prosthesis type). We estimated midterm mortality rates with the Kaplan-Meier method. The troponin I elevation and no troponin I elevation groups were compared using the log-rank test. We performed multivariate logistic regression analysis to identify the independent predictors of troponin I elevation. We included variables in the multivariate models with reference to prior studies and excluded covariates from the multivariate models. Baseline variables with a P-value < 0.05 in the univariate analysis were included in the multivariable models. The threshold for significance was a P-value < 0.05.
Results

Patient and procedural characteristics:
The patient characteristics and procedural demographics are shown in Table I and II. Women were significantly higher in num-MYOCARDIAL INJURY AFTER TAVI Values are expressed as n (%), median (IQR), and mean ± standard deviation. 
Clinical outcomes:
The chi-square test showed no significant difference in 30-day mortality (1% versus 0%, P = 0.17). The myocardial injury group did not have an extended hospital stay or an increased rate of in-hospital adverse events (Table III) . The log-rank test showed no significant difference in 1-year mortality and 1-year acute heart failure rate (1-year mortality: P = 0.57; 1-year acute MYOCARDIAL INJURY AFTER TAVI Figure 3 . Kaplan-Meier curves for 1-year survival. Survival rates were calculated using the Kaplan-Meier method and compared using the log-rank test. Kaplan-Meier curves for 1-year heart failure. Heart failure rates were calculated using the Kaplan-Meier method and compared using the log-rank test.
heart failure rate: P = 0.96) (Figures 3, 4) . Similarly, myocardial injury had no significant relationship with 1-year postoperative onset of atrial fibrillation and 1-year postoperative pacemaker implantation (1-year postoperative onset of atrial fibrillation: P = 0.34; 1-year postoperative pacemaker implantation rate: P = 0.80).
Predictors of myocardial injury:
Age, female sex, balloon aortic valvuloplasty as a bridge therapy, LVEDV, Euro 2 score, and valve type were included in the multivariate models. Age (per 1 increase) (odds ratio [OR]: Nara, ET AL (Table  IV) .
Discussion
Myocardial injury, defined as an elevation in troponin levels, predicts adverse outcomes after percutaneous coronary interventions, coronary artery bypass graft surgery, and noncardiac surgery. [22] [23] [24] Previous studies show that myocardial injury is significantly associated with a high rate of mortality. [4] [5] [6] 16, 17) However, another previous study found that new myocardial necrosis, as evaluated using cardiovascular magnetic resonance imaging, was not observed in post-transfemoral TAVI despite the elevation of the myocardial injury biomarker.
11) Moreover, another recent study demonstrated that periprocedural myocardial injury was unrelated to clinical events. 8, 18) In the present study, periprocedural myocardial injury similarly had no relationship to 30-day and 1-year mortality. Furthermore, it had no influence on the 1-year acute heart failure rate.
The present study showed that the independent predictors of myocardial injury were age, female sex, balloon aortic valvuloplasty as a bridge therapy, LVEDV, and valve type. Previous studies have shown that the non-use of beta-blockers, history of coronary artery disease, peripheral arterial disease, renal insufficiency, left ventricular ejection fraction, procedure time, and prosthesis type of Sapien 3 are predictors of myocardial injury. 5, 6, 8, 18) To our knowledge, the present study is the first to reveal that the use of balloon aortic valvuloplasty as a bridge therapy is related to myocardial injury. The preconditioning effect of balloon aortic valvuloplasty as a bridge therapy might have affected our results. Balloon aortic valvuloplasty as a bridge therapy would improve aortic stenosis temporary and stabilize preoperative condition before TAVI. The smaller LVEDV might have been due to a higher rate of wire injury. Sapien 3 prosthesis had the lowest rate of myocardial injury in the present study. Previous studies have suggested that Sapien 3 valve use tends to have a lower risk. 25, 26) There is a possibility that the less-invasive nature of Sapien 3 might have influenced the study's results. Sapien 3 can be placed via a low-profile 14-Fr expandable sheath and decreased pre-and post-balloon aortic valvuloplasty. The reduced tissue manipulation during TAVI would decrease the chance of myocardial injury. In addition, newer transcatheter valves with lower invasiveness and requiring less manipulation, should decrease myocardial injury. The previous study showed similar results. 18) The rate of Lunderquist wire use was higher in the myocardial injury group than in the non-myocardial injury group. The stiffness of Lunderquist might have influenced wire injury. A pre-shaped wire would be less invasive, with respect to the myocardium.
Rapid pacing time (except for CoreValve) was longer in the myocardial injury group than in the non-myocardial injury group. A larger study might have demonstrated a significant difference. Longer rapid pacing time can decrease coronary flow and injure the myocardial muscle. 14) Periprocedural myocardial injury did not affect the prognosis of TAVI in this study. On the other hand, previous studies indicate that myocardial injury is significantly associated with a high rate of mortality. [4] [5] [6] 16, 17) These studies included patient-caused complications such as annulus rupture, cardiac tamponade, or other serious events. Such patients might have poor prognosis and high level of troponin I. But there were no serious complications in the present study. For that reason, myocardial injury did not affect the prognosis in our paper.
There are several limitations in this study. First, we did not accurately evaluate myocardial injury with images and something. Second, the present study was singlecenter, retrospective, and observational. Prospective evaluations of larger patient populations in multiple centers are necessary to confirm our results.
Conclusions
Myocardial injury after TAVI was not associated with midterm mortality and other clinical event in this study. The high value of troponin I may not be related to prognosis. Age, female sex, valve type, balloon aortic valvuloplasty as a bridge therapy, and LVEDV were predictors of myocardial injury in the present study.
